Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zanidatamab + tislelizumab
- Development stage
- Phase 3
- Lead developer
- Zymeworks
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Zanidatamab + tislelizumab is a combination of two monoclonal antibodies used experimentally in oncology. **Zanidatamab** is a humanized bispecific monoclonal antibody that targets two non-overlapping extracellular domains (domain 2 and domain 4) of HER2, leading to receptor clustering, internalization, downregulation, and induction of immune-mediated cytotoxicity, including antibody-dependent cellular cytotoxicity (ADCC), phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). **Tislelizumab** is a humanized monoclonal antibody against PD-1; it blocks the PD-1/PD-L1 and PD-1/PD-L2 interactions, thereby reducing negative immune signaling and enhancing T-cell activity. The combination is under clinical investigation primarily for HER2-positive advanced or metastatic gastroesophageal adenocarcinoma, in both chemotherapy-containing and chemotherapy-free regimens[2][4][9].
- Brand names
- Ziihera + Tevimbra
- Other names
- zanidatamab + tislelizumabzanidatamab-hrii + tislelizumab-jsgr
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on zanidatamab + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zanidatamab + tislelizumab.